(KR20170037845) The present invention relates to a tripentyl ester of trimellitic acid and, more specifically, to a mixture of triisopentyl esters of trimellitic acid, comprising isomeric pentyl radicals in which more than 5 mol% of the isomeric pentyl radicals contained in the ester mixture are branched. In addition, the mixture has excellent compatibility with PVC and PVC-containing polymers and shows a lower migration tendency. COPYRIGHT KIPO 2017
(JP2017066392) PROBLEM TO BE SOLVED: To provide an aqueous pigment ink for inkjet recording capable of enhancing discharge stability during continuous recording and excellent in dispersibility.SOLUTION: There is provided an aqueous ink for inkjet recording containing a pigment and water and further containing a resin for pigment dispersion containing an ethylene oxide chain and at least one of an anionic surfactant containing an ethylene oxide group and a nonionic surfactant containing an ethylene oxide group.SELECTED DRAWING: None
(JP6108020) PROBLEM TO BE SOLVED: Being the sample water which includes the ammonia of high density, it offers the ion exchange equipment whose it is possible to remove the cation sufficiently, and the anion detection device which can detect the anion securely. SOLUTION: It had valve V13 and valve the cathode room 16 where the anode room 15 where the suffering processing liquid flows flows out and the water flows flows out and the aforementioned anode room the anode and are arranged in the aforementioned cathode room 16 the cathode and the aforementioned anode room the pressure of the cation exchange body and the aforementioned anode room 15 which fill up to the both of 15 which are arranged in the cation exchange membrane 40 which divides 15 and the cathode room 16 and the aforementioned anode room 15 and the aforementioned cathode room 16 as the pressure adjustment expedient which is made higher than pressure of the aforementioned cathode room 16 V15, in the ion exchange equipment and this ion exchange equipmentThe anion detection device which combines electric conductivity total 70.
(WO201760794) Microbiologically safe and healthy drinking water is prepared from raw water by clarifying and disinfecting it with reactive oxygen derivatives and silver ions. Initially, the water is treated with ozone until a suitable concentration of 0.1-0.5 mg/l of ozone in the water is reached, after that the required amount of silver cations disinfectant solution is supplied into the water so that the silver concentration is 0.02-0.1 mg/l. A stable and safe silver disinfectant solution is used without the use of electrolysis equipment. The solution is stabilized with alkaline earth and/or alkali metal cations, which positively complement the overall intake of minerals. By using such a method, the water stored in the open is protected from secondary microbial contamination for a long time, particularly, longer than 3 months.
(US20170096700) The present invention discloses novel oligonucleotide primer sequences BC1, BC2 and BC3 for the identification of Bacillus coagulans. The invention also discloses a PCR based method for the identification of Bacillus coagulants using the aforesaid primers, wherein positive amplification with primer sets BC1, BC2 and negative amplification with primer set BC3 confirms the presence of Bacillus coagulans.
(US20170073676) Methods, compositions, devices, and kits for treating and/or reducing the risk of developing a condition associated with fibrosis and/or collagen deposition are provided. The method of treating and/or reducing the risk of developing a condition associated with fibrosis and/or collagen deposition in a subject includes administering an effective amount a miRNA-762 inhibitor to the subject, wherein the subject is identified as having a risk of developing and/or a need for treatment of the condition associated with fibrosis and/or collagen deposition. The kit includes a vial containing an miRNA-762 inhibitor and a device for use in a surgery creating a risk of fibrosis and/or collagen deposition. The composition includes a pharmaceutical composition comprising a miRNA-762 inhibitor and a second agent selected from the group consisting of: an angiotensin-converting enzyme (ACE) inhibitors, an angiotensin receptor blocker (ARB), another antihypertensive agent, a steroid, and combinations thereof.
YARZABAL ISABELLE;AUBERT THIERRY;LUGEZ PIERRE
(US20170121500) The present invention relates to the field of vulcanization of unsaturated polymers, in particular halogenated, and more particularly chlorinated, unsaturated polymers, such as, for example, polychloroprene, using as vulcanization agent a mixture of bis(2,5-dimercapto-1,3,4-thiadiazole) and at least one organic base. The present invention relates to the process for vulcanization of said polymers with said vulcanization mixture.
(WO201773910) The present invention relates to a method for direct transdifferentiation into neurons using metal nanoparticles magnetized from an electromagnetic field, and to a cell therapeutic agent for the treatment of cerebral nerve diseases, comprising neurons differentiated by the method. In the present invention, it was specifically verified that the direct transdifferentiation efficiency into neurons can be remarkably improved through the above method and the symptoms of cerebral nerve diseases, such as a stroke, can be effectively alleviated. Therefore, in the treatment of degenerative cerebral nerve diseases, the target therapy is expected to be implemented through a more fundamental approach.
(WO201744853) In some embodiments, the present invention provides methods including the steps of providing one or more human somatic cells, causing transient increased expression of OCT4, KLF4, SOX2, and cMYC in the somatic cells forming modified somatic cells, providing a plurality of inactivated embryonic fibroblasts, associating the modified somatic cells with the inactivated embryonic fibroblasts in a culture media comprising 20% KO DMEM xeno-free serum replacement and at least 15 ng/ml recombinant bFGF to form human induced neural stem cells.
(WO201744811) The present disclosure relates to, inter alia, a recombinant eculizumab protein or a recombinant eculizumab variant protein having specific glycosylation patterns. The present disclosure relates to, inter alia, a recombinant eculizumab protein or a recombinant eculizumab variant protein made from CHO cells. The present disclosure also relates to methods for the use of these proteins.